StockMarketWire.com - Pharmaceutical company 4D pharma confirmed Friday the company would be delivering clinical readouts from its lead programmes this year.

4D had two clinical trials underway in cancer and IBS and expected further trials to commence this year in oncology indications and asthma, the company said.

'This is an important year for 4D as we start to see clinical readouts from our lead programmes. Our focus on understanding bacterial function and mechanism to select the most potent single strain Live Biotherapeutics as well as our continued progress to evaluate them in the clinic is reflected in our presentation,' said Duncan Peyton, 4D's Chief Executive Officer.

'4D's approach has numerous advantages including accelerated speed into clinical trials and a clear regulatory pathway to market.'

The update comes as the company announced Friday its participation in the inaugural Chardan Capital Markets LLC Microbiome Medicines Summit.



At 10:22am: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was 0p at 91.4p



Story provided by StockMarketWire.com